Consensus Theriva Biologics, Inc.

Equities

TOVX

US87164U4094

Delayed Nyse Other stock markets 11:37:52 2024-05-13 am EDT			5-day change	1st Jan Change
0.3785 ^USD	+3.98%		-5.38%	-12.00%

May. 07	Theriva Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 23	Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma	CI

Evolution of the average Target Price on Theriva Biologics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

bbec909dea7863c6e562309.lm_oFE-obx3cE3Bpls0OofV8-LgJcmThXNgPsJxV7D8.pxawRC3gKVuoZig-76FE6ZEQnv1KQwaZDbFD58Ud1XivPolMK80JZLJnFw~298b5407cd774d84f4082dcf61f46dc9

Analyst Recommendations on Theriva Biologics, Inc.

Cantor Fitzgerald Initiates Coverage on Synthetic Biologics With Overweight Rating	22-07-20	MT
History shows stocks can weather rate hike cycle	22-03-16	RE
SYNTHETIC BIOLOGICS : Maxim Upgrades Synthetic Biologics to Buy From Hold; Price Target is $2.50	21-03-12	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.364 USD

Average target price

4.5 USD

Spread / Average Target

+1,136.26%

High Price Target

7 USD

Spread / Highest target

+1,823.08%

Low Price Target

2 USD

Spread / Lowest Target

+449.45%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Theriva Biologics, Inc.

Cantor Fitzgerald
Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar